Targeted therapies for prostate cancer

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 2, 2005, Pages 283-298

  Asatiani, Ekatherine ^a   Gelman, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Prostate cancer; Prostate specific antigen (PSA); Prostate specific membrane antigen (PSMA); Vaccine

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ABARELIX; ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA TOCOPHEROL; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CAPROMAB PENDETIDE IN 111; CV 706; CV 787; CYTOTOXIC AGENT; ENDOTHELIN; EVEROLIMUS; GEFITINIB; GONADORELIN AGONIST; IMATINIB; INDIUM 111; L 12ADT; L 377202; LEUPRORELIN; LUTETIUM; LUTETIUM 177; MLN 2704; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PERTUZUMAB; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; PROVENGE; RITUXIMAB; SEMAXANIB; SERINE PROTEINASE; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE MUTATION; HEADACHE; HORMONE DEPENDENCE; HUMAN; MAXIMUM TOLERATED DOSE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; PERIPHERAL EDEMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RHINITIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 18144401721     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.2.283     Document Type: Review

References (178)

1. LO BK: Antibody humanization by CDR grafting. Methods Mol. Biol. (2004) 248:135-159.
2. MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. Blood (1997) 90:2188-2195.
3. NAHTA R, ESTEVA FJ: HER-2-targeted therapy: lessons learned and future directions. Clin. Cancer Res. (2003) 9:5078-5084.
4. LAIRD AD, VAJKOCZY P, SHAWVER LK et al.: SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors. Cancer Res. (2000) 60:4152-4160.
5. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037.
6. WAKELING AE, GUY SP, WOODBURN JR et al.: ZD1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy. Cancer Res. (2002) 62:5749-5754.
7. BROSS PF, KANE R, FARRELL AT et al.: Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. (2004) 10:3954-3964.
8. VOGEL CL, COBLEIGH MA, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 20:719-726.
9. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
10. HUGGINS C, STEVENS RE, HODGES CL: Studies on prostatic cancer II. The effect of castration on clinical patients with carcinoma of the prostate. Arch. Surg. (1941) 43:209.
11. PROSTATE CANCER TRIALISTS' COLLABORATIVE GROUP: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 355:1491-1498.
12. BOLLA M, COLLETTE L, BLANK L et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet (2002) 360:103-106.
13. MESSING EM, MANOLA J, SAROSDY M et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. (1999) 341:1781-1788.
14. GELMANN EP: Molecular biology of the androgen receptor. J. Clin. Oncol. (2002) 20:3001-3015.
15. BERRY W, DAKHIL S, MODIANO M, GREGURICH M, ASMAR L: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J. Urol. (2002) 168:2439-2443.
16. KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. (1999) 17:2506-2513.
17. HUHTANIEMI I, NIKULA H, RANNIKKO S, CLAYTON R: Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists. J. Steroid Biochem. (1986) 24:169-176.
18. MONGIAT-ARTUS P, TEILLAC P: Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. (2004) 5:2171-2179.
19. EISENBERGER MA, BLUMENSTEIN BA, CRAWFORD ED et al.: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. (1998) 339:1036-1042.
20. RASHID MH, CHAUDHARY UB: Intermittent Androgen Deprivation Therapy for Prostate Cancer. Oncologist (2004) 9:295-301.
21. CHEN CD, WELSBIE DS, TRAN C et al.: Molecular determinants of resistance to antiandrogen therapy. Nat. Med. (2004) 10:33-39.
22. CULIG Z, HOBISCH A, CRONAUER MV et al.: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. (1994) 54:5474-5478.
23. CRAFT N, SHOSTAK Y, CAREY M, SAWYERS CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. (1999) 5:280-285.
24. NAZARETH LV, WEIGEL NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. (1996) 271:19900-19907.
25. SOLIT DB, ZHENG FF, DROBNJAK M et al.: 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. (2002) 8:986-993.
26. PIKE J, HOLMES D, KAMALATI T et al.: Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor. Oncogene (2004) 23:7561-7570.
27. TROYER JK, BECKETT ML, WRIGHT GL, JR.: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer (1995) 62:552-558.
28. RINKER-SCHAEFFER CW, HAWKINS AL, SU SL et al.: Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics (1995) 30:105-108.
29. PINTO JT, SUFFOLETTO BP, BERZIN TM et al.: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. (1996) 2:1445-1451.
30. WRIGHT GL, JR., GROB BM, HALEY C et al.: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 48:326-334.
31. ISRAELI RS, POWELL CT, CORR JG, FAIR WR, HESTON WD: Expression of the prostate-specific membrane antigen. Cancer Res. (1994) 54:1807-1811.
32. SWEAT SD, PACELLI A, MURPHY GP, BOSTWICK DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 52:637-640.
33. CHANG SS, REUTER VE, HESTON WD et al.: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59:3192-3198.
34. MILOWSKY MI, ROSMARIN AS, COBHAM MV et al.: Anti-PSMA mAb huJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proceedings of American Society of Clinical Oncology. 21. 2002.
35. RITTER MP: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen Urol.Oncol. (2004) 22:384.
36. KAHN D, WILLIAMS RD, MANYAK MJ et al.: 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J. Urol. (1998) 159:2041-2046.
37. BANDER NH, TRABULSI EJ, KOSTAKOGLU L et al.: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. (2003) 170:1717-1721.
38. MILOWSKY MI, NANUS DM, KOSTAKOGLU L et al.: Phase I Trial of Yttrium-90-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer. J. Clin. Oncol. (2004) 22:2522-2531.
39. BANDER NH, NANUS DM, MILOWSKY MI et al.: Phase I radioimmunotherapy (RIT) trial of humanized monoclonal (mAb) antibody J591 to the extracellular domain of prostate specific membrane antigen (PSMAext) radiolabeled with 177leutetium (177Lu) in advanced prostate cancer (Pca). Proceedings of American Society of Clinical Oncology 22, 401. 2003.
40. BLUM RH, WITTENBERG BK, CANELLOS GP et al.: A therapeutic trial of maytansine. Cancer Clin. Trials (1978) 1:113-117.
41. HENRY MD, WEN S, SILVA MD et al.: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. (2004) 64:7995-8001.
42. BANDER NH, NANUS DM, MILOWSKY MI et al.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol (2003) 30:667-676.
43. NANUS DM, MILOWSKY MI, ROSMARIN AS et al.: Phase II trial of monoclonal antibody huJ591 in combination with low dose subcutaneous interleukin-2 in patients with recurrent prostate cancer (PC). Proceedings of American Society of Clinical Oncology 21. 2002.
44. MAGKLARA A, CHEUNG CC, ASA SL, DIAMANDIS EP: Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clin. Chim. Acta (2000) 300:171-180.
45. POUND CR, PARTIN AW, EISENBERGER MA et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 281:1591-1597.
46. CATALONA WJ, SMITH DS, ORNSTEIN DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA (1997) 277:1452-1455.
47. GOHAGAN JK, LEVIN D, PROROK PC, SULLIVAN D: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin. Trials (2001) 21(Suppl):249S-406S.
48. LILJA H, CHRISTENSSON A, DAHLEN U et al.: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. (1991) 37:1618-1625.
49. DENMEADE SR, LOU W, LOVGREN J et al.: Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. (1997) 57:4924-4930.
50. DIPAOLA RS, RINEHART J, NEMUNAITIS J et al.: Characterization of a Novel Prostate-Specific Antigen-Activated Peptide-Doxorubicin Conjugate in Patients With Prostate Cancer. J. Clin. Oncol. (2002) 20:1874-1879.
51. WONG BK, DEFEO-JONES D, JONES RE et al.: PSA-Specific and Non-PSA-Specific Conversion of a PSA Targeted Peptide Conjugate of Doxorubicin to Its Active Metabolites. Drug Metab. Dispos. (2001) 29:313-318.
52. FURUYA Y, LUNDMO P, SHORT AD, GILL DL, ISAACS JT: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res. (1994) 54:6167-6175.
53. DENMEADE SR, JAKOBSEN CM, JANSSEN S et al.: Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer. J. Natl Cancer Inst. (2003) 95:990-1000.
54. DEWEESE TL, VAN DER POEL H, LI S et al.: A Phase I Trial of CV706, a Replication-competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer following Radiation Therapy. Cancer Res. (2001) 61:7464-7472.
55. YU DC, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59:4200-4203.
56. YU DC, CHEN Y, DILLEY J et al.: Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. (2001) 61:517-525.
57. GULLEY J, CHEN AP, DAHUT W et al.: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 53:109-117.
58. EDER JP, KANTOFF PW, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6:1632-1638.
59. PAVLENKO M, ROOS AK, LUNDQVIST A et al.: A Phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer (2004) 91:688-694.
60. KAUFMAN HL, WANG W, MANOLA J et al.: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. (2004) 22:2122-2132.
61. BUBLEY GJ, CARDUCCI M, DAHUT W et al.: Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group. J. Clin. Oncol. (1999) 17:3461-3467.
62. BURCH PA, BREEN JK, BUCKNER JC et al.: Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. (2000) 6:2175-2182.
63. SMALL EJ, FRATESI P, REESE DM et al.: Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells. J. Clin. Oncol. (2000) 18:3894-3903.
64. BURCH PA, CROGHAN GA, GASTINEAU DA et al.: Immunotherapy (APC8015, Provenge(R)) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase II trial. Prostate (2004) 60:197-204.
65. KYLSTRA JW, NEMUNAITIS J, SMALL EJ, JONES LA: A placebo-controlled Phase III trial of immunotherapy (APC8015, Provenge®) for androgen independent prostate cancer (AIPC): Evidence that Gleason Score predicts immunologic as well as clinical responses to therapy [abstract]. Proceedings of the AACR 2004;45.
66. NELSON WG, DE MARZO AM, ISAACS WB: Prostate cancer. N. Engl. J. Med. (2003) 349:366-381.
67. LIN X, TASCILAR M, LEE WH et al.: GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. (2001) 159:1815-1826.
68. NELSON WG, DE MARZO AM, DEWEESE TL: The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology (2001) 57:39-45.
69. THE ALPHA-TOCOPHEROL, BETA CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. (1994) 330:1029-1035.
70. HEINONEN OP, ALBANES D, VIRTAMO J et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. (1998) 90:440-446.
71. KLEIN EA, THOMPSON IM: Update on chemoprevention of prostate cancer. Curr. Opin. Urol. (2004) 14:143-149.
72. RODRIGUEZ C, JACOBS EJ, MONDUL AM et al.: Vitamin E supplements and risk of prostate cancer in US men. Cancer Epidemiol. Biomarkers Prev. (2004) 13:378-382.
73. BOVA GS, CARTER BS, BUSSEMAKERS JG et al.: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. (1993) 53:3869-3873.
74. EMMERT-BUCK MR, VOCKE CD, POZZATTI RO et al.: Allelic loss on chromosome 8p12-21 in microdissected prostate intraepithelial neoplasia. Cancer Res. (1995) 55:2959-2962.
75. VOCKE CD, POZZATTI RO, BOSTWICK DG et al.: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p21-22. Cancer Res. (1996) 56:2411-2416.
76. SWALWELL JI, VOCKE CD, YANG Y et al.: Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes. Cancer (2002) 33:201-205.
77. BOWEN C, BUBENDORF L, VOELLER HJ et al.: Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. (2000) 60:6111-6115.
78. ASATIANI E, HUANG W -X, WANG A et al.: Deletion, methylation and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. (2005) 65:1164-1173.
79. VOELLER HJ, AUGUSTUS M, MADLIKE V et al.: Coding region of NKX3.1, prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. (1997) 57:4455-4459.
80. ORNSTEIN DK, CINQUANTA M, WEILER S et al.: Expression studies and mutational analysis of the androgen regulated homeobox gene nkx3.1 in benign and malignant prostate epithelium. J. Urol. (2001) 165:1329-1334.
81. BHATIA-GAUR R, DONJACOUR AA, SCIAVOLINO PJ et al.: Roles for Nkx3.1 in prostate development and cancer. Genes Dev. (1999) 13:966-977.
82. KIM MJ, CARDIFF RD, DESAI N et al.: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA (2002) 99:2884-2889.
83. MAGEE JA, ABDULKADIR SA, MILBRANDT J: Haploinsufficiency at the Nkx3.1 locus. A paradigm forstochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell (2003) 3:273-283.
84. LI QL, ITO K, SAKAKURA C et al.: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell (2002) 109:113-124.
85. GIDEKEL S, PIZOV G, BERGMAN Y, PIKARSKY E: Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell (2003) 4:361-370.
86. CARTER BS, EWING CM, WARD WS et al.: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA (1990) 87:8751-8755.
87. FEILOTTER HE, NAGAI MA, BOAG AH, ENG C, MULLIGAN LM: Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 16:1743-1748.
88. HERBST RA, WEISS J, EHNIS A, CAVENEE WK, ARDEN KC: Loss of heterozygosity on chromosome 10q is associated with malignant melanoma. Proc. Amer. Assoc. Cancer Res. (1994) 35:575 AB 3428.
89. LUNDGREN R, KRISTOFFERSSON U, HEIM S, MANDAHL N, MITELMAN F: Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate. Cancer Genet. Cytogenet. (1988) 35:103-108.
90. CAIRNS P, OKAMI K, HALACHMI S et al.: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. (1997) 57:4997-5000.
91. DONG JT, SIPE TW, HYYTINEN ER et al.: PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene (1998) 17:1979-1982.
92. DONG JT, LI CL, SIPE TW, FRIERSON HF, JR.: Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res. (2001) 7:304-308.
93. GRAY IC, STEWART LM, PHILLIPS SM et al.: Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer (1998) 78:1296-1300.
94. MCMENAMIN ME, SOUNG P, PERERA S et al.: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. (1999) 59:4291-4296.
95. WANG SI, PARSONS R, ITTMANN M: Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. (1998) 4:811-815.
96. WHANG YE, WU X, SUZUKI H et al.: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA (1998) 95:5246-5250.
97. ABATE-SHEN C, BANACH-PETROSKY WA, SUN X et al.: Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. (2003) 63:3886-3890.
98. DI CRISTOFANO A, DE ACETIS M, KOFF A, CORDON-CARDO C, PANDOLFI PP: Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. (2001) 27:222-224.
99. KWABI-ADDO B, GIRI D, SCHMIDT K et al.: Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA (2001) 98:11563-11568.
100. PODSYPANINA K, ELLENSON LH, NEMES A et al.: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA (1999) 96:1563-1568.
101. RAMASWAMY S, NAKAMURA N, VAZQUEZ F et al.: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl Acad. Sci USA (1999) 96:2110-2115.
102. GHOSH PM, MALIK S, BEDOLLA R, KREISBERG JI: Akt in prostate cancer: possible role in androgen-independence. Curr. Drug Metab. (2003) 4:487-496.
103. BURROUGHS KD, OH J, BARRETT JC, DIAUGUSTINE RP: Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? Mol. Cancer Res. (2003) 1:312-322.
104. FRANKE TF, YANG SI, CHAN TO et al.: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell (1995) 81:727-736.
105. WEN Y, HU MCT, MAKINO K et al.: HER-2/neu Promotes Androgen-independent Survival and Growth of Prostate Cancer Cells through the Akt Pathway. Cancer Res. (2000) 60:6841-6845.
106. YANG L, WANG L, LIN HK et al.: Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res Commun. (2003) 305:462-469.
107. YU H, NICAR MR, SHI R et al.: Levels of insulin-like growth Factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology (2001) 57:471-475.
108. CHAN JM, STAMPFER MJ, MA J et al.: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl. Cancer Inst. (2002) 94:1099-1106.
109. KANETY H, MADJAR Y, DAGAN Y et al.: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. (1993) 77:229-233.
110. MIYATA Y, SAKAI H, HAYASHI T, KANETAKE H: Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate (2003) 54:125-132.
111. LI L, YU H, SCHUMACHER F, CASEY G, WITTE JS: Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control (2003) 14:721-726.
112. WOODSON K, TANGREA JA, POLLAK M et al.: Serum insulin-like growth Factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. (2003) 63:3991-3994.
113. ISMAIL HA, POLLAK M, BEHLOULI H et al.: Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU. Int. (2003) 92:699-702.
114. GRAFF JR, KONICEK BW, MCNULTY AM et al.: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Mol. Chem. (2000) 275:24500-24505.
115. MURILLO H, HUANG H, SCHMIDT LJ, SMITH DI, TINDALL DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology (2001) 142:4795-4805.
116. SHI XB, MA AH, TEPPER CG et al.: Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate (2004) 60:257-271.
117. MALIK SN, BRATTAIN M, GHOSH PM et al.: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. (2002) 8:1168-1171.
118. DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Eng. J. Med. (2002) 347:472-480.
119. APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. (2002) 347:481-487.
120. GLEICH GJ, LEIFERMAN KM, PARDANANI A, TEFFERI A, BUTTERFIELD JH: Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet (2002) 359:1577-1578.
121. PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
122. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Eng. J. Med. (2004) 350:2129-2139.
123. HUMBLET Y: Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert. Opin. Pharmacother. (2004) 5:1621-1633.
124. CROWDER RJ, LOMBARDI DP, ELLIS MJ: Successful targeting of ErbB2 receptors-is PTEN the key? Cancer Cell (2004) 6:103-104.
125. SIGNORETTI S, MONTIRONI R, MANOLA J et al.: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. (2000) 92:1918-1925.
126. CARLES J, LLORETA J, SALIDO M et al.: Her-2/neu expression in prostate cancer: a dynamic process? Clin. Cancer Res. (2004) 10:4742-4745.
127. ROSS JS, SHEEHAN CE, HAYNER-BUCHAN AM et al.: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer (1997) 79:2162-2170.
128. OXLEY JD, WINKLER MH, GILLATT DA, PEAT DS: Her-2/neu oncogene amplification in clinically localised prostate cancer. J. Clin. Pathol. (2002) 55:118-120.
129. SAVINAINEN KJ, SARAMAKI OR, LINJA MJ et al.: Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol. (2002) 160:339-345.
130. COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J. Clin. Oncol. (1999) 17:2639.
131. MORRIS MJ, REUTER VE, KELLY WK et al.: HER-2 profiling and targeting in prostate carcinoma. Cancer (2002) 94:980-986.
132. LARA PN, JR., CHEE KG, LONGMATE J et al.: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer (2004) 100:2125-2131.
133. ZIADA A, BARQAWI A, GLODE LM et al.: The use of trastuzumab in the treatment of hormone refractory prostate cancer; Phase II trial. Prostate (2004) 60:332-337.
134. SMALL EJ, BOK R, REESE DM, SUDILOVSKY D, FROHLICH M: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin. Oncol. (2001) 28:71-76.
135. PESCHE S, LATIL A, MUZEAU F et al.: PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene (1998) 16:2879-2883.
136. NAGATA Y, LAN KH, ZHOU X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6:117-127.
137. FRANKLIN MC, CAREY KD, VAJDOS FF et al.: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 5:317-328.
138. AGUS DB, AKITA RW, FOX WD et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 2:127-137.
139. AGUS DB, GORDON M, TAYLOR C et al. Clinical activity in a Phase I trial of HER-2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies (AST). Proc. Am. Soc. Clin. Oncol. (2003) 22:92 (Abstract).
140. BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20:4292-4302.
141. BONACCORSI L, MARCHIANI S, MURATORI M, FORTI G, BALDI E: Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. J. Cancer Res. Clin. Oncol. (2004) 130:604-614.
142. SIROTNAK FM, SHE Y, LEE F, CHEN J, SCHER HI: Studies with CWR22 Xenografts in Nude Mice Suggest That ZD1839 May Have a Role in the Treatment of Both Androgen-dependent and Androgen-independent Human Prostate Cancer. Clin. Cancer Res. (2002) 8:3870-3876.
143. BARTON J, BLACKLEDGE G, WAKELING A: Growth factors and their receptors: new targets for prostate cancer therapy. Urology (2001) 58:114-122.
144. WILLIAMS KJ, TELFER BA, STRATFORD IJ, WEDGE SR: ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorecral cancer xenograft model. Br. J. Cancer (2002) 86:1157-1161.
145. HUANG S, ARMSTRONG EA, BENAVENTE S, CHINNAIYAN P, HARARI PM: Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor. Cancer Res. (2004) 64:5355-5362.
146. BIANCO R, CAPUTO R, CAPUTO R et al.: Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin. Cancer Res. (2004) 10:4858-4864.
147. MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838-4848.
148. RAO K, GOODIN S, LEVITT MJ et al.: A Phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate (2005) 62:115-122.
149. TIFFANY NM, WERSINGER EM, GARZOTTO M, BEER TM: Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology (2004) 63:934-939.
150. MATHEW P, THALL PF, JONES D et al.: Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular Phase I trial in androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22:3323-3329.
151. NESHAT MS, MELLINGHOFF IK, TRAN C et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA (2001) 98:10314-10319.
152. GRUNWALD V, DEGRAFFENRIED L, RUSSEL D et al.: Inhibitors of mTOR Reverse Doxorubicin Resistance Conferred by PTEN Status in Prostate Cancer Cells. Cancer Res. (2002) 62:6141-6145.
153. MAJUMDER PK, FEBBO PG, BIKOFF R et al.: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. (2004) 10:594-601.
154. STROHMEYER D, STRAUSS F, ROSSING C et al.: Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anti-Cancer Res. (2004) 24:1797-1804.
155. TROJAN L, THOMAS D, KNOLL T et al.: Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol. Res. (2004) 32:97-103.
156. GADDIPATI JP, MANI H, SHEFALI et al.: Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA). Anti-Cancer Res. (2000) 20:2547-2552.
157. LISSBRANT IF, HAMMARSTEN P, LISSBRANT E et al.: Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate (2004) 58:57-65.
158. GEORGE DJ, HALABI S, SHEPARD TF et al.: Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. (2001) 7:1932-1936.
159. SHARIAT SF, ANWURI VA, LAMB DJ et al.: Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy. J. Clin. Oncol. (2004) 22:1655-1663.
160. BOK RA, HALABI S, FEI DT et al.: Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study. Cancer Res. (2001) 61:2533-2536.
161. STADLER WM, CAO D, VOGELZANG NJ et al.: A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer. Clin. Cancer Res. (2004) 10:3365-3370.
162. YOWELL CW, DAAKA Y: G protein-coupled receptors provide survival signals in prostate cancer. Clin. Prostate Cancer (2002) 1:177-181.
163. PIANETTI S, ARSURA M, ROMIEU-MOUREZ R, COFFEY RJ, SONENSHEIN GE: Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene (2001) 20:1287-1299.
164. CHEN CD, SAWYERS CL: NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell Biol. (2002) 22:2862-2870.
165. SUH J, RABSON AB: NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J. Cell. Biochem. (2004) 91:100-117.
166. LESSARD L, MES-MASSON AM, LAMARRE L et al.: NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int. (2003) 91:417-420.
167. PAPANDREOU CN, LOGOTHETIS CJ: Bortezomib as a Potential Treatment for Prostate Cancer. Cancer Res. (2004) 64:5036-5043.
168. SMITH PC, HOBISCH A, LIN DL, CULIG Z, KELLER ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. (2001) 12:33-40.
169. CULIG Z, BARTSCH G, HOBISCH A: Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell Endocrinol. (2002) 197:231-238.
170. MICHALAKI V, SYRIGOS K, CHARLES P, WAXMAN J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer (2004) 91:1227.
171. LEVIN ER: Endothelins. N. Engl. J. Med. (1995) 333:356-363.
172. LANGENSTROER P, TANG R, SHAPIRO E et al.: Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J. Urol. (1993) 150:495-499.
173. NELSON JB, HEDICAN SP, GEORGE DJ et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. (1995) 1:944-949.
174. YIN JJ, MOHAMMAD KS, KAKONEN SM et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA (2003) 100:10954-10959.
175. CARDUCCI MA, NELSON JB, BOWLING MK et al.: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. (2002) 20:2171-2180.
176. ZONNENBERG BA, GROENEWEGEN G, JANUS TJ et al.: Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin. Cancer Res. (2003) 9:2965-2972.
177. CARDUCCI MA, PADLEY RJ, BREUL J et al.: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. J. Clin. Oncol. (2003) 21:679-689.
178. YUYAMA H, NOGUCHI Y, FUJIMORI A et al.: Superiority of YM598 over atrasentan as a selective endothelin ET(A) receptor antagonist. Eur. J. Pharmacol. (2004) 498:171-177.